Publications

Clinical and genomic characteristics of small-cell lung cancer in never-smokers →

Thomas, A, Mian, I, Tlemsani, C, Pongor, L, Takahashi, N, Maignan, K, Snider, J, Li, G, Frampton, GM, Ali, SM, Kim, S, Nichols, S, Rajapakse, V, Guha, U, Sharon, E, Fujimoto, J, Moran, CA, Witstuba, II, Wei, JS, Szabo, E, Torres, AZ, Carson, KR

May 2020

Manuscript

Chest

Flatiron-authored

Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort →

Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM

May 2020

Abstract

AACR Annual Meeting

A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer →

Lu, MW, Walia, G, Schulze, K, Doral, MY, Maund, SL, Gaffey, S, Cabili, MN, Bourla, AB, Green, RJ, Santos, EC, Herbst, RS, Chiang, AC, Schwartzberg, L

May 2020

Abstract

ASCO Annual Meeting

Flatiron-authored

Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy →

Yang, DX, Jairam, V, Park, HS, Decker, RH, Chiang, AC, Gross, CP, Yu, JB

May 2020

Abstract

ASCO Annual Meeting

Methodological approaches for incorporating real-world data (RWD) for overall survival (OS) into long-term survival estimates: a case-study nice technology appraisal in extensive-stage small-cell lung cancer (ES-SCLC) →

Connor, S, Orfanos, P, Flahavan, EM, Patterson, K, Lee, D

November 2019

Abstract

EU ISPOR

A landmark response analysis to determine cost-effectiveness of third-line nivolumab for small cell lung cancer →

Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y

November 2019

Abstract

EU ISPOR

A partitioned survival model to determine cost-effectiveness of third-line nivolumab monotherapy for small cell lung cancer →

Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y

November 2019

Abstract

EU ISPOR

New treatment option for ES-SCLC: Patient characteristics and use of an atezolizumab regimen in the real-world setting →

McCune, S, Ton, TGN, Whipple, S, Induru, RR, Horn, L, Percent, IJ, Mekhail, T, Goldschmidt, Jr., J, Leal, TA, MacVicar, GR, Braiteh, F, Daniel, DB, Hussein, M, Mansfield, AS, Lam, S, Johnson, A, Morris, S, Spira, A

September 2019

Abstract

World Conference on Lung Cancer

Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials →

Carrigan G, Whipple S, Capra WB, Taylor MD, Brown JS, Lu M, Arnieri B, Copping R, Rothman KJ

July 2019

Manuscript

Clinical Pharmacology and Therapeutics

Treatment characteristics and clinical outcomes in patients with extensive-stage small cell lung cancer treated with carboplatin or cisplatin in combination with etoposide in US clinical practice →

Sebastian M, Barlesi F, Califano R, Mansfield AS, Blackhall F, Flahavan E, Davies J, Arnold P, Morris S, Reck M

April 2019

Abstract

European Lung Cancer Conference

Establishing the Need for Immuno-Oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC) →

Schwartzberg L

October 2018

Abstract

ESMO Annual Congress

Distinctive Clinical Characteristics of SCLC in Never-Smokers →

Mian I, Nichols S, Abernethy AP, Carson K, Maignan K, Torres AZ, Snider J, Frampton G, Li G, Sharon E, Szabo E, Thomas A

September 2018

Abstract

World Conference on Lung Cancer

Flatiron-authored

Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC) →

Schwartzberg L, Korytowsky B, Penrod J, Yuan Y, Gu T, Le TK, Abraham P, Selvaggi G

September 2018

Abstract

World Conference on Lung Cancer